RWE study of the US’ largest COVID-19 database shows that COVID-19 vaccine protected the majority of cancer patients

• The study used one of the largest COVID-19 real world databases in the world, with over 12.5 million patients, including 4.5 million COVID-19 patients.
• Key findings from the analysis were:
• The risk of breakthrough infection was reduced after the second vaccine dose for all cancers.
• Patients with hematologic cancers, or blood cancers, including leukemia, multiple myeloma and lymphoma, were at a higher risk of breakthrough COVID; those with blood cancers had a greater risk than solid cancers.
• The Moderna vaccine was more effective than the Pfizer vaccine for protecting patients with hematologic cancers, especially patients with multiple myeloma.

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.

About DISTILL

DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

Ref: RWEAPR2022BRA